hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06283069, orgStudyIdInfo id: 45C301, briefTitle: Relationship Between Lifestyle Indicators and Cardiovascular Clinical Parameters, acronym: RICH, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2033-04-30, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Istituto Auxologico Italiano, class: OTHER, descriptionModule briefSummary: The goal of the study is to build a Register accruing data derived from the compilation of the questionnaire about LifeStyle for a population both of adults and of young boys and girls. The investigators are confident that in this way they will be able to expand the database they already have. The investigators will be able to increase the strength of the correlations between LS indices and health indicators. In particular, the investigators will emphasize the relationship between physical activity, stress, and diet quality on one hand, and on the other, they will focus on physiological parameters, like arterial pressure, gluco-lipid profile, and possible pathologies., conditionsModule conditions: Cardiovascular Diseases, conditions: Lifestyle, conditions: Nutrition, Healthy, conditions: Physical Inactivity, conditions: Stress, conditions: Sleep, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: compilation of a questionnaire about LifeStyle, outcomesModule primaryOutcomes measure: weekly physical activity volume, secondaryOutcomes measure: nutrition quality, secondaryOutcomes measure: weight, secondaryOutcomes measure: height, secondaryOutcomes measure: blood pressure, secondaryOutcomes measure: perception of stress, fatigue, and somatic symptoms, secondaryOutcomes measure: glycemia, secondaryOutcomes measure: cholesterol, secondaryOutcomes measure: creatinine, secondaryOutcomes measure: waist circumference, secondaryOutcomes measure: heart rate, eligibilityModule sex: ALL, minimumAge: 6 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istituto Auxologico Italiano, status: RECRUITING, city: Milan, country: Italy, contacts name: Luca Giovanelli, MD, role: CONTACT, phone: +3902619112808, email: luca.giovanelli@unimi.it, contacts name: Daniela Lucini, Prof, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06283056, orgStudyIdInfo id: DO611073A, briefTitle: RF Microneedling With Multi-Depth Targeting Per Insertion for The Treatment of Cellulite, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-06-16, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: InMode MD Ltd., class: INDUSTRY, descriptionModule briefSummary: The aim of the study is to evaluate the safety and efficacy of Morpheus 8 Body 40-pin tip up to 7mm depth Applicator for subdermal treatment of cellulite appearance, skin laxity, and subcutaneous fat deposits., conditionsModule conditions: Cellulitis of Leg, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Prospective, open-label clinical study., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Device treatment, outcomesModule primaryOutcomes measure: Cellulite assessment based on Clinician Reported Photonumeric Cellulite Severity Scale, primaryOutcomes measure: Cellulite assessment based on DiBernardo Photonumeric Cellulite Severity Scale, secondaryOutcomes measure: Subject assessment of improvement, secondaryOutcomes measure: Subject assessment of improvement, secondaryOutcomes measure: Subject assessment of improvement, secondaryOutcomes measure: Subject assessment of satisfaction, secondaryOutcomes measure: Subject assessment of satisfaction, secondaryOutcomes measure: Subject assessment of satisfaction, secondaryOutcomes measure: Investigator assessment of the skin appearance improvemen, secondaryOutcomes measure: Investigator assessment of the skin appearance improvement, secondaryOutcomes measure: Investigator assessment of the skin appearance, secondaryOutcomes measure: Investigator assessment of the cellulite following subdermal Morpheus8 treatment, secondaryOutcomes measure: Investigator assessment of the cellulite following subdermal Morpheus8 treatment, secondaryOutcomes measure: Investigator assessment of the cellulite following subdermal Morpheus8 treatment, otherOutcomes measure: Adverse Event rate, otherOutcomes measure: Pain Scale, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dermatology & Laser Surgery Center of New York, status: ACTIVE_NOT_RECRUITING, city: New York, state: New York, zip: 10028, country: United States, geoPoint lat: 40.71427, lon: -74.00597, locations facility: Dallas Plastic Surgeon, status: RECRUITING, city: Dallas, state: Texas, zip: 75225, country: United States, contacts name: Lily Hays, role: CONTACT, phone: 214-821-9114, email: Lily Hays <lily.hays@dpsi.org>, geoPoint lat: 32.78306, lon: -96.80667, hasResults: False
protocolSection identificationModule nctId: NCT06283043, orgStudyIdInfo id: 2022/3749, briefTitle: Effect of Motor Function, Depression and Sleep Quality on Attention in Parkinson's Disease, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-05, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Inonu University, class: OTHER, descriptionModule briefSummary: Our study was planned to analyze motor function, endurance and sleep attention information in Parkinson's patients with detailed and objective measurements., conditionsModule conditions: Movement Disorders (Incl Parkinsonism), conditions: Parkinsonian Disorders, conditions: Attention Impaired, conditions: Movement Disorders, Functional, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 54, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: TUG, primaryOutcomes measure: 10 m walking test, primaryOutcomes measure: 30 sec sit-stand test, primaryOutcomes measure: berg balance test, primaryOutcomes measure: one leg stance test, primaryOutcomes measure: functional reach test, primaryOutcomes measure: hand dinamometer, primaryOutcomes measure: mobil application, primaryOutcomes measure: Pittsburg Sleep Quality İndex, primaryOutcomes measure: Beck Depression, primaryOutcomes measure: P300, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Inonu University, city: Malatya, state: Battalgazi, zip: 44280, country: Turkey, geoPoint lat: 38.35018, lon: 38.31667, hasResults: False
protocolSection identificationModule nctId: NCT06283030, orgStudyIdInfo id: IM-001, briefTitle: Evaluation of Hypoglossal Nerve Stimulation in Humans With Obstructive Sleep Apnea, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-12-01, primaryCompletionDateStruct date: 2023-09-25, completionDateStruct date: 2023-09-25, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Invicta Medical Inc., class: INDUSTRY, collaborators name: Vanderbilt University Medical Center, descriptionModule briefSummary: This proof-of-concept study is being performed to evaluate whether the hypoglossal nerve can be stimulated using a small series of electrodes placed surgically via a percutaneous approach. Minimally invasive off the shelf medical devices will be used and observation of the characteristic physiological responses to stimulation of the HGN, will be assessed., conditionsModule conditions: Sleep Apnea, conditions: Sleep Apnea, Obstructive, conditions: Sleep Apnea Syndromes, conditions: Sleep Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ACTUAL, armsInterventionsModule interventions name: Hypoglossal nerve stimulation, outcomesModule primaryOutcomes measure: Identification and access of the target outcomes, primaryOutcomes measure: Tongue protrusion outcomes, primaryOutcomes measure: Characterization of electrode array outcomes, primaryOutcomes measure: Electrode array placement and removal outcomes, primaryOutcomes measure: Safety outcomes, eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Vanderbilt Bill Wilkerson Centre, city: Nashville, state: Tennessee, zip: 37232, country: United States, geoPoint lat: 36.16589, lon: -86.78444, hasResults: False
protocolSection identificationModule nctId: NCT06283017, orgStudyIdInfo id: IM-002, briefTitle: Evaluation of the Effects of Hypoglossal Nerve Stimulation in Humans With Obstructive Sleep Apnea, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-06-01, primaryCompletionDateStruct date: 2024-03, completionDateStruct date: 2024-03, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Invicta Medical Inc., class: INDUSTRY, collaborators name: Adelaide Institute for Sleep Health, Flinders University, descriptionModule briefSummary: This proof-of-concept study is being performed to evaluate whether the hypoglossal nerve can be stimulated using a small series of electrodes placed surgically via a percutaneous approach. Minimally invasive off the shelf medical devices will be used and observation of the characteristic physiological responses to stimulation of the HGN, will be assessed., conditionsModule conditions: Sleep Apnea, conditions: Sleep Apnea, Obstructive, conditions: Sleep Disorder, conditions: Sleep Apnea Syndromes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 14, type: ACTUAL, armsInterventionsModule interventions name: Hypoglossal nerve stimulation, outcomesModule primaryOutcomes measure: Target identification and access outcomes, primaryOutcomes measure: Tongue protrusion outcomes, primaryOutcomes measure: Characterization of lead placement outcomes, primaryOutcomes measure: Lead placement and removal outcomes, primaryOutcomes measure: Safety outcomes, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Adelaide Institute for Sleep Health, Flinders University, city: Adelaide, state: South Australia, zip: 5042, country: Australia, geoPoint lat: -34.92866, lon: 138.59863, hasResults: False
protocolSection identificationModule nctId: NCT06283004, orgStudyIdInfo id: 2024-1/30, briefTitle: Investigation of Walking Training With Different Slope Types in COPD Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-06-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Acibadem University, class: OTHER, collaborators name: Bezmialem Vakif University, descriptionModule briefSummary: Chronic obstructive pulmonary disease (COPD) is a disease that continues to generate a great deal of research and this research must continue, both because it is not completely curable and because of the large patient population. The importance and benefits of exercise training in COPD patients are clear. One of the most preferred types of exercise training is the so-called aerobic exercise training, which typically takes the form of walking. A typical walking training does not use a slope or may include an uphill slope. However, recently there have been publications about downhill walking and its benefits in COPD. Walking on a level, uphill, and downhill slope may have the potential to result in different gains by using different muscle groups more. Therefore, this study aimed to compare the effects of walking training on exercise capacity, respiratory functions, muscle strength, and functional status in COPD patients with three different slope types: level, uphill, and downhill., conditionsModule conditions: Pulmonary Disease, Chronic Obstructive, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 51, type: ESTIMATED, armsInterventionsModule interventions name: Downhill walking training, interventions name: Level walking training, interventions name: Uphill walking training, outcomesModule primaryOutcomes measure: 6 Minutes Walking Distance (6MWD), primaryOutcomes measure: Spirometric measurements (Forced vital capacity), primaryOutcomes measure: Spirometric measurements (First second forced expiratory volume), primaryOutcomes measure: Spirometric measurements (FEV1/FVC ratio), primaryOutcomes measure: Spirometric measurements (Peak Expiratory Flow), primaryOutcomes measure: Spirometric measurements (Maximum Intermediate Expiratory Flow), primaryOutcomes measure: Muscle strength measurements (skeletal muscles), primaryOutcomes measure: Muscle strength measurements (respiratory muscles), primaryOutcomes measure: 30-second sit and stand test, primaryOutcomes measure: Functional performance inventory, secondaryOutcomes measure: Dyspnea, secondaryOutcomes measure: Fatigue, secondaryOutcomes measure: Level of exertion, eligibilityModule sex: ALL, minimumAge: 40 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06282991, orgStudyIdInfo id: B7461028, briefTitle: A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-07-22, primaryCompletionDateStruct date: 2021-01-18, completionDateStruct date: 2021-01-18, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Pfizer, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to learn about lorlatinib for the possible treatment of lung cancer which could not be controlled.This study is seeking participants who:* have lung cancer that could not be controlled.* have a type of gene called anaplastic lymphoma kinase. A gene is a part of your DNA that has instructions for making things your body needs to work.* have received at least 1 treatment before.All participants in this study had received lorlatinib. Lorlatinib is a tablet that is taken by mouth at home. They continued to take dacomitinib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective., conditionsModule conditions: Non-Small Cell Lung Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: OTHER, enrollmentInfo count: 73, type: ACTUAL, armsInterventionsModule interventions name: Lorlatinib, outcomesModule primaryOutcomes measure: The treatment pattern from initial diagnosis to current lorlatinib treatment., secondaryOutcomes measure: objective response rate (ORR), secondaryOutcomes measure: overall survival, secondaryOutcomes measure: progression-free survival, secondaryOutcomes measure: 1-year OS rate, secondaryOutcomes measure: time-to-treatment failure for all NSCLC, secondaryOutcomes measure: time-to-treatment failure of lorlatinib, secondaryOutcomes measure: The clinical nature, incidence, duration, and severity of lorlatinib-related safety profile, eligibilityModule sex: ALL, minimumAge: 20 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: CHANG GUNG MEMORIAL HOSPITAL Kaohsiung Branch, city: Kaohsiung City, zip: 83301, country: Taiwan, geoPoint lat: 22.61626, lon: 120.31333, locations facility: Chung Shan Medical University Hospital, city: Taichung, zip: 402, country: Taiwan, geoPoint lat: 24.1469, lon: 120.6839, locations facility: Taichung Veterans General Hospital, city: Taichung, zip: 407219, country: Taiwan, geoPoint lat: 24.1469, lon: 120.6839, locations facility: National Taiwan University Hospital, city: Taipei, zip: 100, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, locations facility: Taipei Veterans General Hospital, city: Taipei, zip: 11217, country: Taiwan, geoPoint lat: 25.04776, lon: 121.53185, locations facility: Chang Gung Memorial Hospital - Linkou Branch, city: Taoyuan City, zip: 333, country: Taiwan, geoPoint lat: 24.95233, lon: 121.20193, hasResults: False
protocolSection identificationModule nctId: NCT06282952, orgStudyIdInfo id: 198/2023, briefTitle: NEwborn Infant of a Mother With Obesity - Fecal Microbiome Transplantation, RCT, acronym: NEMO-FMT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: Oulu University Hospital, class: OTHER, collaborators name: University of Oulu, collaborators name: University of Turku, collaborators name: Turku University Hospital, collaborators name: University of Helsinki, collaborators name: Academy of Finland, collaborators name: Biocenter Oulu, descriptionModule briefSummary: The goal of this clinical trial is to investigate the differences in microbiota, height and weight between infants born by cesarean section to obese mothers and randomized to receive fecal microbiota transplant after birth. The main questions it aims to answer are:* Could fecal transplant be used improve gut microbiota and prevent overweight or obesity.* Is the source of colonization a modifiable factor and can it be changed by using an early fecal microbiota transplant., conditionsModule conditions: Fecal Microbiota Transplantation, conditions: Cesarean Section, conditions: Overweight and Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The eligible women are randomized into two groups in which their newborns receive either fecal microbiota transplant from 1) their own mother (50 newborns) or 2) the Microbiome Biobank (50 newborns). The randomization 1:1 is done in blocks of 4 mothers. The study is double blinded. If mother has Group B streptococcus colonization or other infectious disease described in table 1, and microbiota transplant cannot be given or if mother will have non-elective-CS and the microbiome transplant is not available, the mother is included in 3) the observational cohort, which is "open" (not blinded)., primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, maskingDescription: The research statistician performs the computer-generated randomization. The study nurse prepares the fecal transplant according to the randomization. Study participants or investigators are not aware of study group., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Fecal transplant, outcomesModule primaryOutcomes measure: Microbial composition profiles in fecal sample, primaryOutcomes measure: Height in centimeters, primaryOutcomes measure: Height z-score, primaryOutcomes measure: Weight in kilograms, primaryOutcomes measure: Weight-for-length (%), secondaryOutcomes measure: The source of colonization by exclusively shared genes (ESGs), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 49 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06282939, orgStudyIdInfo id: 20234314, briefTitle: Optima Coil Performance in The Interventional Management of Intracranial Aneurysms Registry, acronym: OPTIMA, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2026-12-01, completionDateStruct date: 2027-12-01, studyFirstPostDateStruct date: 2024-02-28, lastUpdatePostDateStruct date: 2024-02-28, sponsorCollaboratorsModule leadSponsor name: HCA Healthcare Research Institute, class: OTHER, collaborators name: Balt USA, descriptionModule briefSummary: This is a prospective, open-label, consecutive enrollment, multi-center, U.S. registry of patients with intracranial aneurysms who are treated with the Optima Coil System.The primary objective of this registry is to evaluate the safety and effectiveness of the OptimaTM Coil System, including the OptiMAX Coils, in the real-world treatment of intracranial aneurysms. Imaging will be analyzed by a designated core neuroimaging lab to assess procedural success and aneurysm occlusion rates. Intent to treat population total: 700 patients 600 patients, up to 100 screen failures., conditionsModule conditions: Intracranial Aneurysm, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: OPTIMA and OPTIMAX Coils manufactured by Balt USA, outcomesModule primaryOutcomes measure: Measure Adequate Occlusion Using modified Raymond-Roy Occlusion Class (MRRC) I and II score, primaryOutcomes measure: Assess coiling alone or in combination with adjunctive devices for approximately 400 patients, primaryOutcomes measure: Evaluate Coiling with flow diversion for approximately 200 subjects, primaryOutcomes measure: Subgroup analyses will be performed examining:, primaryOutcomes measure: Analyze outcomes of small aneurysms defined as smaller than 5mm, secondaryOutcomes measure: Adequate occlusion, secondaryOutcomes measure: Packing density, secondaryOutcomes measure: Complete occlusion, secondaryOutcomes measure: Complete occlusion, secondaryOutcomes measure: Recanalization rate, secondaryOutcomes measure: Retreatment rate, secondaryOutcomes measure: Change in degree of disability, secondaryOutcomes measure: The number of coils used in an aneurysm, secondaryOutcomes measure: Procedural fluoroscopic time, otherOutcomes measure: Primary Safety Endpoint, otherOutcomes measure: Secondary Safety Endpoint, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Med City Plano, status: RECRUITING, city: Plano, state: Texas, zip: 75075, country: United States, contacts name: Albert Yoo, role: CONTACT, phone: 972-566-5411, email: ajyoo74@gmail.com, contacts name: Pauline Matheri, role: CONTACT, phone: 615-329-7274, email: Pauline.Matheri@HCAhealthcare.com, geoPoint lat: 33.01984, lon: -96.69889, hasResults: False